It looks like you're using an Ad Blocker.
Please white-list or disable AboveTopSecret.com in your ad-blocking tool.
Some features of ATS will be disabled while you continue to use an ad-blocker.
VeriChip Corporation (“VeriChip”) (NASDAQ: CHIP - News) and its development partner RECEPTORS LLC, a technology company whose AFFINITY by DESIGN™ chemistry platform can be applied to the development of selective binding products, announced today that VeriChip plans to fund its existing partnership with RECEPTORS to continue the development of a triage detection system for detection of the H1N1 virus. As previously announced in April 2009, the partners executed a Memorandum of Understanding relating to the expansion of their development partnership and published a white paper entitled, "An Integrated Sensor System for the Detection of Bio-Threats from Pandemics to Emerging Diseases to Bioterrorism," which is available at www.verichipcorp.com...
Scott R. Silverman, Chairman and CEO of VeriChip, stated, "Since the strengthening of our balance sheet upon the receipt of almost $4.5 million at the end of July, we have focused on how to effectively use our working capital. The first decision was to acquire Steel Vault and form PositiveID to converge personal health records and secure personal financial information. The second is this – the funding and strengthening of our partnership with RECEPTORS to develop a first-of-its-kind H1N1 and other virus early detection system. As PositiveID continues to take form, we look to expand the breadth and depth of our identification technology and tool offerings and capabilities."
RECEPTORS' Patent No. 7,504,364 titled “Methods of Making Arrays and Artificial Receptors” and Patent No. 7,469,076 “Sensors Employing Combinatorial Artificial Receptors” are currently being applied to the development of diagnostic and sensor platforms for microbial pathogens and other biological threats.
Following VeriChip's announcement on September 8, 2009, that it has agreed to acquire Steel Vault Corporation (OTCBB: SVUL - News) and form PositiveID Corporation, a provider of identification technologies and tools for consumers and businesses, the companies will now fund the first phase of the triage detection system development. The companies plan to release more specific details of the functionality and the timing of the triage detection system next week.
A Florida-based company that boasts selling the world's first and only federally approved radio microchip for implanting in humans is now turning its development branch toward "emergency preparedness," hoping to produce an implant that can automatically detect in its host's bloodstream the presence of swine flu or other viruses deemed a "bio-threat."
VeriChip Corporation currently sells a small, under-the-skin Radio Frequency Identification capsule, or RFID, that patients can opt to have implanted, containing a number computer-linked to their medical records, enabling doctors with a special reader to access the information even if the patient is unconscious or unidentified. The company boasts its microchip, roughly the size of a grain of rice, is the only such implant approved by the U.S. Food and Drug Administration.
Natural and human events combine to produce a steady stream of biological threats to
health and safety. These threats range from pandemic flu and multiple-resistant
pathogens like "MRSA" (Staphylococcus aureus) to food borne salmonella and E. coli.
The diversity of sources, threats and consequences produce a very challenging
environment for detection, diagnosis and alert. More significantly, failure to meet the
detection and identification challenge results in a range of consequences, from massive
food recalls and economic loss to morbidity and mortality. To meet this challenge, a
wide variety of products have been introduced ranging from single threat diagnostics to
prototype surveillance sensor systems. However, these responses to the market have
limitations in stability and scalability and, in particular, their dependence on inherently
unstable biological agents, like antibodies, places severe limits on both their economics
and applications. Most importantly, these products are generally targeted to a single
agent, which may not resemble the next threat. Clearly, what is needed is a sensor
system that is stable and scalable to meet the demands of an impending pandemic and
capable of spanning the range of specificity from a generic pathogenic virus alert to a
multiplexed response and read-out for continuous surveillance. The combination of
RECEPTORS' CARA platform and VeriChip's signal transduction and communication
capabilities provides both the technology and the expertise required to build an integrated
bio-threat sensor system.
As the public questions H1N1 vaccine content, it's been another Orwellian packed two weeks "with technology running at a faster pace than Superman" states Greg Nick, director of two groups, Mankind vs VeriChip and We The People Will Not Be Chipped.
These groups participate in empowering learning opportunities for making wise decisions about matters such as human chipping.
The VeriChip is implanted with a syringe, raising concern about the H1N1 vaccine since independent researchers have debunked that there is a pandemic (Dina Rosendorff for PM, Australian Broadcasting Company, August 18, 2009) and there is a hard-sell vaccine marketing campaign aimed at fifty percent of Americans willingly accepting the H1N1 vaccine.
Independent researchers such a those associated with the Center for Research on Globalization concur that the H1N1 exercise is a global military based operation using pharmacological warfare
VeriChip Corporation (“VeriChip”) (NASDAQ: CHIP - News) and its development partner RECEPTORS LLC, a technology company whose AFFINITY by DESIGN™ chemistry platform can be applied to the development of selective binding products, announced today that VeriChip has been granted an exclusive license to RECEPTORS' Patent No. 7,504,364 titled “Methods of Making Arrays and Artificial Receptors” and Patent No. 7,469,076 “Sensors Employing Combinatorial Artificial Receptors,” in their application to the development of the virus triage detection system for the H1N1 virus. The patents can also be applied to detection systems for other viruses and biological threats such as Methicillin-resistant Staphylococcus aureus (MRSA).
Originally posted by Sliadon
I had a scary conversation with a friend the other day... But first read this article from 2007:
That was technology that TPTB allowed to be reported... I'm sure that RFID chips even smaller than that exist now.
Going out on a limb, lets say population control isn't the goal of this. Rather, the goal is to implant these chips into everyone. With the size of the chips being so miniscule, whats to stop Big Pharma from dropping a chip into each vial of the vaccine? As a result, all recipients of the vaccine are now "chipped" and we have all heard the doom and gloom about the chips being activated with our information on them and if TPTB don't approve our actions, they turn our chips off, and in essence we no longer exist as we can't access our credit cards or banks or any information anymore.
Whoa Nelly, a storm is on the horizon....
Originally posted by burntheships
The part I wonder about...and call me crazy is when they finally get this to run off of the energy our own body makes....
Originally posted by zorgon
It would be easy to just 'adjust' those scanners we all but ignore to scan for other chips
September 21 2009
VeriChip Corporation Granted Exclusive License to Patents Used in Virus Triage Detection System for H1N1 Virus
Virus triage detection system being developed in conjunction with partner, RECEPTORS, will help process patient samples
DELRAY BEACH, FL and CHASKA, MN – September 21, 2009 -- VeriChip Corporation (“VeriChip”) (NASDAQ: CHIP) and its development partner RECEPTORS LLC, a technology company whose AFFINITY by DESIGN™ chemistry platform can be applied to the development of selective binding products, announced today that VeriChip has been granted an exclusive license to RECEPTORS' Patent No. 7,504,364 titled “Methods of Making Arrays and Artificial Receptors” and Patent No. 7,469,076 “Sensors Employing Combinatorial Artificial Receptors,” in their application to the development of the virus triage detection system for the H1N1 virus. The patents can also be applied to detection systems for other viruses and biological threats such as Methicillin-resistant Staphylococcus aureus (MRSA).